Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Firms Fear Diminished Role In Revised EU Signal Detection Guideline

Executive Summary

The European Medicines Agency recently revised its guideline on signal management to clarify the roles and responsibilities of concerned stakeholders and related terminology, among other things. However, the industry believes that these key aspects need to be further addressed to ensure that the role of marketing authorization holders is not diminished and that there is clarity on procedural aspects, such as calculating the Day 0.


Related Content

Pharma Buoyed By Preview Of 'Helpful Changes' To EMA's Signal Management Guide
EMA To Address Industry Concerns in Revised Signal Management Guideline





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts